Click the star to add/remove an item to/from your individual schedule.
You need to be logged in to avail of this functionality.

P067


Landing policies and practices for access to medicines at dizzying prices 
Convenors:
Pierre-Marie DAVID (Université de Montréal)
Marie-Eve Bouthillier (University of Montreal)
Jean-Christophe Belisle-Pipon (Simon Fraser University)
Send message to Convenors
Format:
Traditional Open Panel
Location:
HG-10A20
Sessions:
Wednesday 17 July, -
Time zone: Europe/Amsterdam

Short Abstract:

This panel questions practices and policies around high-cost drugs. We welcome contributions from papers which help to understand how these pharmaceuticals are shaped in order to have their prices skyrocketing, and how some -parallel and exceptional- landing areas for their access are constructed.

Long Abstract:

High-cost drugs are a particular type of technology at the heart of major transformations in healthcare systems. The increasing pressure to bring promising drugs to the market entails key STS considerations on how some pharmaceuticals have been able to break through all the glass ceilings hitherto established in terms of price on the one hand. And how, on the other hand, these 'unaffordable' drugs have been offered new “landing grounds” in medical practice and patient access. The aim of this panel is to examine this dual movement altogether.

This panel will attend to question practices and policies around pharmaceuticals at unaffordable prices. We welcome contributions from papers which help to understand how these pharmaceuticals are shaped in order to have their prices skyrocketing, and how some -parallel and exceptional- landing areas for their access are constructed. We invite papers that could answer some of the following questions:

- Which areas are conducive to price explosions (oncology, rare diseases) and how these areas are culturally and technologically organized?

- What are the procedures for establishing these areas?

- What other epistemological and scientific arrangements are needed?

- What are the role and practices of pharmacoeconomics that make this possible?

- What are the areas that allow at least transient use of such drugs?

- How are exceptional access programmes organised and structured?

- What are the major scientific and political issues involved in these parallel access routes?

Accepted papers:

Session 1 Wednesday 17 July, 2024, -